Repatha vs Losartan: Head-to-Head Efficacy Comparison

Different Drug Classes, Different Therapeutic Goals

Evolocumab and losartan belong to entirely separate pharmacological categories, and comparing them requires acknowledging that they do not compete for the same receptor, the same biomarker, or the same clinical indication. Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), increasing hepatic LDL receptor recycling and producing dramatic drops in circulating LDL cholesterol 1. Losartan selectively blocks the angiotensin II type 1 (AT1) receptor, reducing peripheral vascular resistance and aldosterone secretion to lower systemic blood pressure 2.

The question "Is Repatha better than losartan?" assumes a shared outcome metric. That assumption is wrong. A patient with familial hypercholesterolemia and an LDL of 190 mg/dL on maximally tolerated statin therapy needs evolocumab. A patient with stage 2 hypertension and no lipid abnormality needs losartan. The drugs overlap only in the broad category of cardiovascular risk reduction, which is why cross-trial comparisons require careful framing. The 2018 AHA/ACC Multisociety Cholesterol Guideline states that PCSK9 inhibitors should be considered "in patients with clinical ASCVD who are judged to be at very high risk and whose LDL-C level remains ≥70 mg/dL on maximally tolerated statin and ezetimibe therapy" 3. The 2017 ACC/AHA Hypertension Guideline, by contrast, recommends ARBs as first-line agents for blood pressure control in patients with stage 1 or stage 2 hypertension 4. These are parallel treatment pathways, not competing ones.

FOURIER: Evolocumab's Cardiovascular Evidence

The FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) enrolled 27,564 patients with established atherosclerotic cardiovascular disease already receiving statin therapy. Patients were randomized to evolocumab (140 mg every 2 weeks or 420 mg monthly) or placebo. Over a median follow-up of 2.2 years, evolocumab reduced LDL cholesterol from a median of 92 mg/dL to 30 mg/dL, a 59% relative reduction 1.

The primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) occurred in 9.8% of the evolocumab group vs 11.3% in the placebo group, yielding a hazard ratio of 0.85 (95% CI, 0.79 to 0.92; P<0.001) 1. The key secondary endpoint of cardiovascular death, MI, or stroke showed a 20% relative risk reduction (HR 0.80; 95% CI, 0.73 to 0.88; P<0.001). Lead investigator Marc S. Sabatine, MD, MPH, of Brigham and Women's Hospital noted that "the benefits of evolocumab were consistent across all prespecified subgroups, including patients with diabetes, those over age 65, and those with baseline LDL cholesterol below 70 mg/dL" 1.

One limitation: FOURIER did not show a statistically significant reduction in cardiovascular death as an individual endpoint (HR 1.05; 95% CI, 0.88 to 1.25). The trial's 2.2-year follow-up may have been too short to capture mortality benefits, a point debated in subsequent analyses 5.

LIFE: Losartan's Cardiovascular Protection

The LIFE trial (Losartan Intervention For Endpoint reduction in hypertension) took a different approach entirely. It enrolled 9,193 patients aged 55 to 80 with essential hypertension and ECG-confirmed left ventricular hypertrophy (LVH), randomizing them to losartan-based or atenolol-based treatment. Over a mean follow-up of 4.8 years, the losartan group showed a 13% reduction in the primary composite endpoint of cardiovascular death, stroke, or myocardial infarction (HR 0.87; 95% CI, 0.77 to 0.98; P=0.021) 2.

The stroke reduction drove much of this benefit. Fatal and non-fatal stroke decreased by 25% in the losartan arm compared with atenolol (HR 0.75; 95% CI, 0.63 to 0.89; P=0.001), despite similar blood pressure reductions in both groups 2. This finding suggested that losartan's cardiovascular protection extended beyond simple blood pressure lowering, likely through AT1 receptor-mediated effects on vascular remodeling, endothelial function, and left ventricular mass regression.

Björn Dahlöf, MD, PhD, who led the LIFE study, described the results as evidence that "the choice of antihypertensive agent matters beyond the millimeters of mercury achieved" 2. Losartan also demonstrated a 25% lower rate of new-onset diabetes compared with atenolol (HR 0.75; 95% CI, 0.63 to 0.88; P=0.001), a secondary finding that influenced subsequent prescribing patterns for metabolically at-risk hypertensive patients 6.

Cross-Trial Comparison: Why the Numbers Don't Directly Translate

Placing FOURIER's 15% MACE reduction next to LIFE's 13% composite reduction tempts a conclusion that evolocumab is marginally more effective. That conclusion is not supported by the data. The two trials enrolled fundamentally different populations, used different comparators, measured different composite endpoints, and ran for different durations.

FOURIER compared evolocumab to placebo on top of background statin therapy in patients with stable ASCVD. LIFE compared losartan to atenolol (not placebo) in hypertensive patients with LVH. The FOURIER placebo arm already received high-intensity statins, meaning evolocumab's benefit was additive to aggressive lipid management. The LIFE comparator, atenolol, is an active antihypertensive agent, meaning losartan's benefit emerged despite both arms achieving comparable blood pressure control 2.

Consider these distinctions when interpreting the trial data:

Population differences. FOURIER patients had a median age of 63 years, 75% were male, and all had confirmed ASCVD. LIFE patients had a mean age of 67 years, 46% were female, and the qualifying condition was hypertension with LVH, not prior atherosclerotic events 1 2.

Endpoint composition. FOURIER's primary endpoint included five components (CV death, MI, stroke, unstable angina hospitalization, coronary revascularization). LIFE's primary endpoint included three (CV death, stroke, MI). The broader FOURIER composite captured more events, inflating the denominator.

Follow-up duration. FOURIER ran 2.2 years; LIFE ran 4.8 years. Longer follow-up in LIFE allowed more time for events to accumulate and for treatment effects to mature.

Comparator intensity. Evolocumab was compared to placebo (maximum contrast). Losartan was compared to atenolol (active comparator, minimum contrast). This asymmetry alone makes percentage comparisons misleading.

Who Should Take Which Drug

The prescribing decision between evolocumab and losartan is rarely an either/or choice. These drugs address separate risk factors that frequently coexist in the same patient.

Evolocumab is indicated for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), or clinical ASCVD who need additional LDL lowering beyond statins and ezetimibe. The 2018 AHA/ACC guideline positions PCSK9 inhibitors as add-on therapy after maximally tolerated statins, not as first-line agents 3. Candidates typically have LDL cholesterol persistently ≥70 mg/dL (for very high-risk ASCVD) or ≥100 mg/dL (for primary prevention in HeFH) despite oral therapy.

Losartan is indicated for hypertension, diabetic nephropathy in patients with type 2 diabetes and proteinuria, and stroke risk reduction in hypertensive patients with LVH 4. The RENAAL trial (N=1,513) demonstrated that losartan reduced the risk of doubling of serum creatinine by 25% and end-stage renal disease by 28% compared to placebo in type 2 diabetic nephropathy 7. This renal protective effect has no equivalent in evolocumab's evidence base.

A 62-year-old with prior MI, LDL of 85 mg/dL on rosuvastatin 40 mg, blood pressure of 148/92 mmHg, and type 2 diabetes with microalbuminuria may need both drugs simultaneously. Evolocumab addresses residual lipid-driven risk. Losartan addresses hypertension and offers nephroprotection. These are complementary, not competitive, prescriptions.

Safety and Tolerability

Evolocumab's safety profile in FOURIER was comparable to placebo for most serious adverse events. Injection site reactions occurred in 2.1% of evolocumab patients vs 1.6% on placebo. Neurocognitive events drew early attention, but the dedicated EBBINGHAUS substudy (N=1,974) found no difference in cognitive function between evolocumab and placebo over a median of 19 months 8. Myalgia rates were similar between groups. The main practical barrier is the subcutaneous injection route and the need for cold-chain storage.

Losartan's side effect profile reflects decades of ARB class experience. Common adverse effects include dizziness (2.4%), upper respiratory infection, and hyperkalemia, particularly in patients with renal impairment or those taking potassium-sparing diuretics 4. ARBs are contraindicated in pregnancy (category D) due to fetal renal toxicity. Angioedema occurs rarely but is less frequent than with ACE inhibitors.

Neither drug causes the metabolic disruptions associated with older cardiovascular agents. Evolocumab does not raise blood glucose. Losartan does not worsen lipid profiles. In LIFE, losartan actually reduced new-onset diabetes by 25% compared with atenolol 6. Both are well-tolerated in long-term use, though adherence patterns differ: oral daily dosing (losartan) generally achieves higher compliance than biweekly or monthly injections (evolocumab) 9.

Cost and Access

The cost gap between these two drugs is massive. Evolocumab carries a wholesale acquisition cost of approximately $5,850 per year, though manufacturer copay programs and insurance negotiations reduce out-of-pocket costs for many patients 3. Prior authorization is standard, and payers typically require documented statin intolerance or inadequate LDL response on maximally tolerated oral therapy before approving coverage.

Losartan has been available as a generic since 2010. A 30-day supply of losartan 50 mg or 100 mg costs between $4 and $10 at most retail pharmacies. No prior authorization is required. This 50-to-1 cost ratio means that losartan is accessible to virtually any insured or uninsured patient, while evolocumab access depends heavily on insurance formulary placement and appeals processes.

Cost-effectiveness analyses have shaped prescribing behavior for PCSK9 inhibitors. An ICER review initially rated evolocumab's value as low at the original list price of $14,100/year, prompting Amgen to reduce the price by 60% in 2018 10. Even at the reduced price, evolocumab's cost-per-QALY remains higher than most generic antihypertensives. For health systems operating under budget constraints, this gap influences which patients receive PCSK9 inhibitors and how aggressively clinicians pursue prior authorization.

When Patients Need Both Drugs

Cardiometabolic risk is rarely one-dimensional. A patient with ASCVD, residual hyperlipidemia on statin therapy, and concurrent hypertension benefits from addressing both LDL cholesterol and blood pressure simultaneously. The combination of evolocumab and losartan has no pharmacokinetic interaction. They are metabolized through different pathways (evolocumab through proteolytic degradation as a monoclonal antibody; losartan through CYP2C9 and CYP3A4 hepatic metabolism), and co-administration does not require dose adjustment for either agent 1 7.

The more clinically relevant question is sequencing. Blood pressure control and statin optimization should precede PCSK9 inhibitor initiation in most cases. The 2018 AHA/ACC guideline explicitly positions PCSK9 inhibitors after statins and ezetimibe have been tried 3. Losartan or another first-line antihypertensive is typically started early in a patient's treatment course, often years before a PCSK9 inhibitor becomes necessary. By the time a clinician considers adding evolocumab, blood pressure management with an ARB, ACE inhibitor, or calcium channel blocker is usually already established.

For the patient with both elevated LDL and hypertension, the evidence supports using both drug classes as part of a comprehensive risk reduction strategy that includes statin therapy, blood pressure control, glycemic management if diabetic, and lifestyle modification including dietary changes and regular physical activity 3 4.